+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies



Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies



Expert Review of Proteomics 14(6): 499-514



Major Depressive Disorder (MDD) is the leading cause of global disability, and an increasing body of literature suggests different cerebrospinal fluid (CSF) proteins as biomarkers of MDD. The aim of this review is to summarize the suggested CSF biomarkers and to analyze the MDD proteomics studies of CSF and brain tissues for promising biomarker candidates. Areas covered: The review includes the human studies found by a PubMed search using the following terms: 'depression cerebrospinal fluid biomarker', 'major depression biomarker CSF', 'depression CSF biomarker', 'proteomics depression', 'proteomics biomarkers in depression', 'proteomics CSF biomarker in depression', and 'major depressive disorder CSF'. The literature analysis highlights promising biomarker candidates and demonstrates conflicting results on others. It reveals 42 differentially regulated proteins in MDD that were identified in more than one proteomics study. It discusses the diagnostic potential of the biomarker candidates and their association with the suggested pathologies. Expert commentary: One ultimate goal of finding biomarkers for MDD is to improve the diagnostic accuracy to achieve better treatment outcomes; due to the heterogeneous nature of MDD, using bio-signatures could be a good strategy to differentiate MDD from other neuropsychiatric disorders. Notably, further validation studies of the suggested biomarkers are still needed.

(PDF emailed within 0-6 h: $19.90)

Accession: 059937767

Download citation: RISBibTeXText

PMID: 28562112

DOI: 10.1080/14789450.2017.1336435


Related references

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers. Arquivos de Neuro-Psiquiatria 71(9b): 689-692, 2014

Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders 37: 65-71, 2017

Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder. Psychiatry Research 254: 244-250, 2017

An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Journal of Proteome Research 14(2): 654-663, 2016

Does refining the phenotype improve replication rates? A review and replication of candidate gene studies on Major Depressive Disorder and Chronic Major Depressive Disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 171b(2): 215-236, 2016

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Comprehensive Psychiatry 68: 34-39, 2017

Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid. Acta Neurologica Belgica 2018, 2018

Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 76: 12-18, 2017

Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia. Journal of Psychiatric Research 113: 190-198, 2019

Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder. International Journal of Neuropsychopharmacology 22(4): 261-269, 2019

Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochemical and Biophysical Research Communications 497(2): 683-688, 2018

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research 47(3): 401-406, 2014

Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. Plos One 10(3): E0121975, 2016

Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology 17(9): 573-579, 2007

Cerebrospinal fluid D-serine concentrations in major depressive disorder negatively correlate with depression severity. Journal of Affective Disorders 226: 155-162, 2017